Sök i LIBRIS databas

  Utökad sökning


Sökning: onr:"swepub:oai:DiVA.org:uu-147270" > Phase II trial of z...

  • d'Amore, Francesco (författare)

Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma

  • Artikel/kapitelEngelska2010


  • LIBRIS-ID:oai:DiVA.org:uu-147270
  • 10.1111/j.1365-2141.2010.08298.xdoi
  • 20629661pmid
  • urn:nbn:se:uu:diva-147270urn

Ingår i deldatabas


  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype
  • Ämneskategori:ref swepub-contenttype


  • Published
  • 11
  • <p>The efficacy and safety of zanolimumab (HuMax-CD4) in patients with relapsed or refractory peripheral T Cell lymphoma (PTCL) was evaluated. Twenty-one adult patients with relapsed or refractory CD4+ PTCL of non-cutaneous type (angioimmunoblastic T cell lymphoma (AITL) n = 9, PTCL-not otherwise specified (NOS) n = 7, anaplastic large cell lymphoma (ALCL) n = 4 and enteropathy type T cell lymphoma n = 1) were treated in a single-arm multi-centre study, with weekly intravenous infusions of zanolimumab 980 mg for 12 weeks. Median age was 69 years (range 26-85). Seventeen of the patients had advanced stage disease (Ann Arbor stages III-IV). Objective tumour responses were obtained in 24% of the patients with two complete responses unconfirmed (CRu) and three partial responses (PR). One of the CRus lasted more than 252 d. Responses were obtained in different PTCL entities: AITL (n = 3), ALCL (n = 1) and PTCL-NOS (n = 1). In general, the trial drug was well tolerated with no major toxicity. Zanolimumab at a dose of 980 mg weekly demonstrated clinical activity and an acceptable safety profile in this poor-prognosis patient population, suggesting that the potential benefit combining zanolimumab with standard chemotherapy in the treatment of PTCL should be investigated.</p>

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Radford, John(SwePub:) (författare)
  • Relander, Thomas(SwePub:) (författare)
  • Jerkeman, Mats(SwePub:) (författare)
  • Tilly, Herve(SwePub:) (författare)
  • Österborg, Anders(SwePub:) (författare)
  • Morschhauser, Franck(SwePub:) (författare)
  • Gramatzki, Martin(SwePub:) (författare)
  • Dreyling, Martin(SwePub:) (författare)
  • Bang, Bo(SwePub:) (författare)
  • Hagberg, Hans,Uppsala universitet, Enheten för onkologi(SwePub:) (författare)

Sammanhörande titlar

  • Ingår i:British Journal of Haematology0007-10481365-2141150:5, s. 565-573


Hitta via bibliotek

Till lärosätets databas

pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy